VIP Stabilizes the Cytoskeleton of Schlemm’s Canal Endothelia via Reducing Caspase‐3 Mediated ZO‐1 Endolysosomal Degradation

Xiaotong Lou, Qianxue Mou, Bowen Zhao, Jingqiu Huang, Ke Yao, Zhaoxia Luo, Meng Ye, Yuanyuan Hu, Qiming Duan, Xing Li, Wen Zheng, Zhiqi Chen, Hong Zhang, Yin ZhaoOxidative 2021 · DOI

TL;DR

Glaucoma, characterized by elevated intraocular pressure (IOP), damages the Schlemm's canal (SC) endothelium, leading to impaired aqueous humor outflow. This study reveals that vasoactive intestinal peptide (VIP) protects SC cells by preventing the degradation of a key junction protein, ZO-1, which is mediated by caspase-3. This finding suggests VIP as a potential therapeutic target for glaucoma.

What Problem Does This Paper Address?

Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness, primarily driven by elevated intraocular pressure (IOP). While the exact mechanisms are complex, impaired drainage of aqueous humor (AH) through the trabecular meshwork (TM) and Schlemm's canal (SC) pathway is a major contributor. The SC endothelium acts as a critical filtration barrier, and its integrity is crucial for maintaining normal IOP. Previous research has indicated that oxidative stress, vascular dysregulation, and aging can damage this barrier, leading to increased outflow resistance. Specifically, changes in the SC endothelium's cytoskeleton, particularly the actin filaments and junctional proteins like ZO-1, are implicated in this process. However, the precise molecular mechanisms by which oxidative stress affects SC integrity and how this can be therapeutically targeted remain areas of active investigation. This paper aims to elucidate the role of vasoactive intestinal peptide (VIP) in stabilizing the SC cytoskeleton and preventing damage, particularly focusing on its interaction with ZO-1 and the caspase-3 pathway.

Methods

The researchers employed a multi-pronged approach combining in vitro and in vivo models.

  • Animal Models: Chronic ocular hypertension (COH) was induced in rats via episcleral venous cauterization. These COH rats were then treated with topical VIP.
  • Cell Culture: Human umbilical vein endothelial cells (HUVECs) and HEK 293 cells were used to investigate cellular mechanisms. Oxidative stress was induced using hydrogen peroxide (H2O2).
  • Molecular Biology Techniques:
    • Transmission Electron Microscopy (TEM): Used to visualize the ultrastructure of SC junctions.
  • Immunofluorescence Staining: To assess the localization and expression levels of ZO-1 and F-actin.
  • Western Blotting: To quantify protein levels of ZO-1, cleaved caspase-3, and other relevant proteins.
  • FITC-Dextran Permeability Assay: To measure the paracellular permeability of the SC inner wall, indicating barrier function.
  • siRNA Knockdown: To reduce the expression of ZO-1 and caspase-3 to study their functional roles.
  • Overexpression Studies: To increase the levels of caspase-3 and ZO-1.
  • Caspase-3 Activity Assay: To directly measure caspase-3 enzymatic activity.
  • Co-immunoprecipitation (Co-IP): To investigate the interaction between cleaved caspase-3 and ZO-1.
  • Endolysosomal Pathway Inhibition: Using chloroquine and MG-132 to determine the role of lysosomal and proteasomal degradation pathways.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • COH Disrupts SC Integrity: Chronically elevated IOP in rats led to significant disruption of SC endothelial cell junctions and a marked decrease in ZO-1 expression in the inner SC wall. This suggests a breakdown in the SC's barrier function.
  • ZO-1 is Crucial for Cytoskeletal Organization: Knocking down ZO-1 in HEK 293 cells, especially under oxidative stress, led to increased F-actin polymerization and disorganized F-actin distribution, highlighting ZO-1's role in maintaining cytoskeletal stability.
  • VIP Protects SC from Oxidative Damage: VIP treatment in both in vivo (COH rats) and in vitro (HUVECs) models attenuated the decrease in ZO-1 levels and improved junctional integrity, reducing SC permeability.
  • Caspase-3 is the Culprit: The study identified caspase-3 as a key mediator in the oxidative stress-induced reduction of ZO-1. Inhibiting caspase-3 activity protected ZO-1 levels and improved SC barrier function.
  • ZO-1 Degradation via Endolysosomal Pathway: Caspase-3 activation promotes the degradation of ZO-1, not through direct cleavage into fragments, but via the endolysosomal pathway, as evidenced by colocalization with endosomal and lysosomal markers. VIP's protective effect involves inhibiting this caspase-3-mediated degradation.
  • VIP's Dual Action: VIP appears to stabilize the SC cytoskeleton by preventing ZO-1 degradation through caspase-3 inhibition, thereby maintaining F-actin organization and reducing cell stiffness, ultimately improving AH outflow.

Key Results

  • COH rats showed increased intercellular width and decreased ZO-1 fluorescence intensity in the SC inner wall compared to controls.
  • FITC-dextran permeability was significantly higher in COH rats, indicating a compromised SC barrier.
  • H2O2 treatment in HUVECs reduced ZO-1 levels and increased the F/G-actin ratio, which was reversed by VIP treatment.
  • Knockdown of ZO-1 in HEK 293 cells led to increased F/G-actin ratio and F-actin disorganization.
  • VIP treatment significantly reduced cleaved caspase-3 levels and caspase-3 activity in H2O2-treated HUVECs.
  • Inhibition of caspase-3 activity (using Ac-DEVD-CHO) rescued ZO-1 levels and distribution.
  • Overexpression of caspase-3 led to ZO-1 reduction, and this effect was partially reversed by VIP.
  • Co-immunoprecipitation showed an interaction between cleaved caspase-3 and ZO-1, which was reduced by VIP.
  • Chloroquine (lysosomal inhibitor) reversed ZO-1 reduction induced by caspase-3 activation, suggesting endolysosomal degradation.
  • VIP treatment in COH rats restored SC ultrastructure and ZO-1 expression, and reduced FITC-dextran leakage.

Limitations and Future Work

  • Caspase-3 Catalytic Activity: While VIP was shown to reduce cleaved caspase-3 levels, further experiments are needed to determine if VIP directly inhibits the catalytic activity of caspase-3 or acts upstream.
  • Autophagy Pathway: The study acknowledges that the lysosomal inhibitor chloroquine also affects autophagy, and thus, the role of the autophagy pathway in ZO-1 degradation cannot be entirely excluded.
  • ZO-1 Cleavage Products: The absence of detectable ZO-1 cleavage fragments in H2O2-treated HUVECs suggests that caspase-3-mediated ZO-1 reduction occurs through mechanisms other than direct cleavage into fragments, which warrants further investigation.
  • VIP's Role in TG Mice: While VIP attenuated F-actin redistribution in a mouse model with spontaneous SC F-actin redistribution, further studies are needed to clarify if this effect is ZO-1-dependent in these mice.
  • Therapeutic Translation: While promising, the study suggests that VIP could be a targeted strategy for glaucoma treatment, implying that future work would involve clinical trials to assess its efficacy and safety in human patients.

Summary updated

Abstract

This study provides insights into the role of VIP in stabilizing the interaction between the actin cytoskeleton and cell junctions and may provide a promising targeted strategy for glaucoma treatment.
BibTeX
@inproceedings{lou2021vip,
  author = {Xiaotong Lou and Qianxue Mou and Bowen Zhao and Jingqiu Huang and Ke Yao and Zhaoxia Luo and Meng Ye and Yuanyuan Hu and Qiming Duan and Xing Li and Wen Zheng and Zhiqi Chen and Hong Zhang and Yin Zhao},
  title = {{VIP Stabilizes the Cytoskeleton of Schlemm’s Canal Endothelia via Reducing Caspase‐3 Mediated ZO‐1 Endolysosomal Degradation}},
  booktitle = {Oxidative},
  year = {2021},
  doi = {10.1155/2021/9397960},
}
Figure